



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Konopitzky *et al.*

Appl. No. 09/631,863

Filed: August 3, 2000

For: **Tumor-Associated Antigen (R11)**

Confirmation No.: 8920

Art Unit: 1642

Examiner: Minh-Tam Davis

Atty. Docket: 0652.2480001/EKS/CML

#17/B
Jm
6/18/03

Amendment And Reply Under 37 C.F.R. § 1.111

Commissioner for Patents
Washington, D.C. 20231

Sir:

RECEIVED

JUN 20 2003

TECH CENTER 1600/2900

In reply to the Office Action dated December 18, 2002, (PTO Prosecution File Wrapper Paper No. 15), Applicants submit the following Amendment and Remarks. This Amendment is provided in the following format:

- (A) A clean version of each replacement paragraph/section/claim along with clear instructions for entry;
- (B) Starting on a separate page, appropriate remarks and arguments. 37 C.F.R. § 1.111 and M.P.E.P. § 714; and
- (C) Starting on a separate page, a marked-up version entitled: "Version with Markings to Show Changes Made."

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor